BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 6, 2026
Home » Authors » John Fox

Articles by John Fox

Research sheds light on Purkinje neurons

June 11, 2014
By John Fox
HONG KONG – A comprehensive catalogue of proteins manufactured in specific parts of Purkinje neurons that was obtained using sophisticated new techniques may improve the understanding of diseases associated with those cells, such as ataxias and autism, possibly leading to the development of badly needed treatments for such disorders, reported researchers from the Riken Institute in Japan.
Read More

Research sheds more light on Purkinje neurons

June 11, 2014
By John Fox
HONG KONG – A comprehensive catalogue of proteins manufactured in specific parts of Purkinje neurons that was obtained using sophisticated new techniques may improve our understanding of diseases associated with these cells, such as ataxias and autism, possibly leading to the development of badly needed treatments for such disorders, report researchers from the Riken Institute in Japan.
Read More

Afinitor shown to delay tumor growth in HER2+ advanced breast cancer

June 4, 2014
By John Fox
HONG KONG – Adding the oral molecular targeted therapy Afinitor (everolimus, Novartis AG) to conventional chemotherapy plus anti-HER2 treatment reduced the risk of progression of human epidermal growth factor receptor-2 (HER2) positive advanced breast cancer resistant to Herceptin (trastuzumab, Roche AG) by 22 percent and may provide clues to the mechanisms underlying Herceptin resistance, researchers report.
Read More

Afinitor shown to delay tumor growth in HER2+ advanced breast cancer

June 4, 2014
By John Fox
HONG KONG – Adding the oral molecular targeted therapy Afinitor (everolimus, Novartis AG) to conventional chemotherapy plus anti-HER2 treatment reduced the risk of progression of human epidermal growth factor receptor-2 (HER2)-positive advanced breast cancer resistant to Herceptin (trastuzumab, Roche AG) by 22 percent and may provide clues to the mechanisms underlying Herceptin resistance, researchers reported.
Read More

Further doubts cast on purported STAP stem cell technique

May 14, 2014
By John Fox
HONG KONG – Chinese University of Hong Kong (CUHK) researchers reported being unable to replicate controversial research purporting to create stimulus-triggered acquisition of pluripotent (STAP) stem cells, which behave like induced pluripotent stem (iPS) cells, by simple acid-based treatment of somatic cells, suggesting that the method is not as simple or as straightforward as initially claimed.
Read More

Further doubts cast on purported STAP stem cell technique

May 14, 2014
By John Fox
HONG KONG – Chinese University of Hong Kong (CUHK) researchers report being unable to replicate controversial research purporting to create stimulus-triggered acquisition of pluripotent (STAP) stem cells, which behave like induced pluripotent stem (iPS) cells, by simple acid-based treatment of somatic cells, suggesting that the method is not as simple or straightforward as initially claimed.
Read More

Molecular structures are key to blood clotting identified

May 7, 2014
By John Fox
HONG KONG ­– International researchers led by the Shanghai Institute of Materia Medica (SIMM) at the Chinese Academy of Sciences have mapped the detailed structure of a receptor with a key role in platelet activation and blood clotting, which has important implications for development of new treatments for cardiovascular and possibly other diseases.
Read More

Molecular structures are key to blood clotting identified

May 7, 2014
By John Fox
HONG KONG ­– International researchers led by the Shanghai Institute of Materia Medica (SIMM) at the Chinese Academy of Sciences have mapped the detailed structure of a receptor with a key role in platelet activation and blood clotting, which has important implications for development of new treatments for cardiovascular and possibly other diseases.
Read More

Xarelto more effective than warfarin for stroke prevention in Asian AF

May 5, 2014
By John Fox
HONG KONG – The oral anticoagulant Xarelto (rivaroxaban, Johnson & Johnson) is more effective than warfarin for preventing stroke and intracranial hemorrhage (ICH), particularly in Asian patients with atrial fibrillation (AF), Chinese University of Hong Kong (CUHK) scientists have reported.
Read More

New mouse models may revolutionize Alzheimer's research

April 16, 2014
By John Fox
HONG KONG — The creation of two new genetically modified mouse models of Alzheimer's disease by Japanese neuroscientists could revolutionize research into the debilitating neurodegenerative disease and lead to the development of badly needed new treatments.
Read More
Previous 1 2 … 61 62 63 64 65 66 67 68 69 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 5, 2026.
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • Depression concept with human, broken brain and heavy rain

    CROI 2026 highlights depression and cognitive vulnerability in HIV

    BioWorld
    The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 3, 2026
  • Concept art for headache

    Slate Medicines launches with focus on headache disorders

    BioWorld Science
    Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing